D-Cycloserine and Social Skills Training in Autism Spectrum Disorders
This study is currently recruiting participants.
Verified April 2013 by Indiana University
Sponsor:
Indiana University
Collaborator:
Information provided by (Responsible Party):
Indiana University
ClinicalTrials.gov Identifier:
NCT01086475
First received: March 10, 2010
Last updated: April 16, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the effectiveness of D-cycloserine for improving social impairment in child with pervasive developmental disorders (PDD).
| Condition | Intervention | Phase |
|---|---|---|
|
Autistic Disorder Asperger's Disorder Pervasive Developmental Disorder NOS |
Drug: D-cycloserine Drug: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders |
Resource links provided by NLM:
Genetics Home Reference related topics:
Asperger syndrome
Drug Information available for:
Cycloserine
U.S. FDA Resources
Further study details as provided by Indiana University:
Primary Outcome Measures:
- Social Responsiveness Scale (SRS) [ Time Frame: Completed at Basline, Week 6, Week 11 and Week 22 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Clinical Global Impressions Improvement Scale [ Time Frame: Will be completed at each of the Ten Medication Assessment Visits, at the Post-Treatment Assessment and at the 3-month Follow-up Assessment ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 102 |
| Study Start Date: | March 2010 |
| Estimated Study Completion Date: | November 2014 |
| Estimated Primary Completion Date: | November 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: D-cycloserine
Subjects randomized to D-cycloserine will be administered 50 mg 30 minutes prior to each of ten Social Skills Training Sessions
|
Drug: D-cycloserine
50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
Other Name: Seromycin
|
|
Placebo Comparator: Placebo
Subjects randomized to placebo arm will receive placebo pill 30 minutes prior to each of ten Social Skills Training Sessions
|
Drug: Placebo
Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
Other Name: Sugar pill
|
Detailed Description:
This study will evaluate the efficacy of D-Cycloserine given 30 minutes prior to each of 10 weekly Social Skills Training Sessions for the treatment of social impairment in children (ages 5-11 years) with PDD during a randomized placebo-controlled trial. This will examine our central hypothesis that D-cycloserine will enhance learning of social skills in children with PDD's.
Eligibility| Ages Eligible for Study: | 5 Years to 11 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- DSM-IV-TR diagnosis of autism, Asperger's disorder, or PDD not otherwise specified (NOS) base on a semi-structured review of DSM-IV-R criteria and mental status examination as wll as a complete parental history obtained from the Autism Diagnostic Interview-Revised (ADI-R) and a complete systematic patient interview utilizing the Autism Diagnostic Observation Schedule (ADOS).
- Males and females ages 5-11 years.
- Significant social impairment as evidenced by a parent-rated Social Responsiveness Scale (SRS) T-score of 60 or greater.
- TSSA score of 70% or less on both parent questionnaire and child assessment. Children not showing significant impairment in the four specific social skill areas (greetings/goodbyes, conversations, game play, and understanding emotions) targeted by the SST are less likely to benefit from treatment.
- Communication Standard Score of 70 or greater on the Vineland-II.
- Full Scale IQ greater than 70.
- Subjects must not be taking any psychotropic drugs affecting glutamate neurotransmission (riluzole, memantine, acamprosate, topiramate, amantadine, among others). Subjects may not be taking more than two psychotropic drugs. Dosing of all concomitant psychotropic drugs targeting core social and/or communication impairment must be stable for eight weeks prior to randomization. Dosing of all concomitant psychotropic drugs treating other features associated with pervasive developmental disorders (insomnia, inattention, hyperactivity, anxiety, irritability among others0 must be stable for two weeks (with the exception of four weeks for fluoxetine) prior to randomization.
- Able to participate in group SST based on semi-structured parent and child interview.
- Legal guardian has provided written informed consent and the subject has provided written informed assent. Expectation that a majority of subjects will be able to assent but the potential for the younger children and/or those that are cognitively impaired will not be able to assent.
Exclusion Criteria:
- Subjects with diagnoses of Rett's disorder or childhood integrative disorder will not be enrolled since these disorders have a different etiology, course, and treatment response. Furthermore, children with these disorders may not function at a high enough level in terms of cognition or language in order to benefit from the SST.
- Initiation of a new psychosocial intervention within 90 days prior to randomization. Participants who have recently had a significant change in their psychosocial interventions will not be eligible until this intervention has been stable for 90 days in order to avoid confounding results of the study. Stable interventions (e.g., speech and occupational therapy), with the exception of concurrent social skills training, will be allowed to continue during the course of the study. Minor changes in ongoing treatment (e.g., missed therapy sessions due to holiday/vacation; planned break in therapy due to school holidays) are not considered significant.
- Subjects exhibiting significant disruptive, aggressive, self-injurious, or sexually inappropriate behavior will not be eligible for enrollment.
- Presence of current DSM-IV-TR psychiatric disorders that require alternative pharmacotherapy or different treatment including psychotic disorders, or major affective disorders, obsessive-compulsive disorder, panic disorder, or substance related disorders.
- Presence of any medical condition that would make treatment with DCS less safe. Subjects with significant cardiac, hepatic, or renal disease will be excluded due to concerns about pharmacokinetic alterations or adverse effects. Subjects with a history of a seizure disorder are permitted if the subject has been seizure free for 6 months and is currently treated with an anticonvulsant that has been stable for 4 weeks. D-Cycloserine is an U.S. FDA Pregnancy Category C drug. Because of the unknown effects of DCS on the developing human fetus, females of childbearing potential will be given a urine pregnancy test and required to use a suitable form of birth control during the study. A positive pregnancy test result excludes the subject.
- Presence of any other condition that would make the participants unable to comply with the requirements of the study for any reason.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01086475
Contacts
| Contact: Arlene Kohn | 317-944-1990 | aekohn@iupui.edu |
Locations
| United States, Indiana | |
| Riley Hospital for Children | Recruiting |
| Indianapolis, Indiana, United States, 46202 | |
| Contact: Kristen Ponsler-Sipes 317-948-4880 kmponsle@iupui.edu | |
| Contact: Arlene .E Kohn 317-944-1990 aekohn@iupui.edu | |
| Principal Investigator: Noha F. Minshawi, Ph.D. | |
| United States, Ohio | |
| Cincinnati Children's Hospital Medical Center | Recruiting |
| Cincinnati, Ohio, United States, 45229 | |
| Contact: Robert Bermingham 513-803-3602 robert.bermingham@cchmc.org | |
| Principal Investigator: Craig A. Erickson, M.D. | |
Sponsors and Collaborators
Indiana University
Investigators
| Principal Investigator: | Noha F. Minshawi, Ph.D. | Indiana University School of Medicine |
| Principal Investigator: | Craig A. Erickson, M.D. | Children's Hospital Medical Center, Cincinnati |
More Information
No publications provided
| Responsible Party: | Indiana University |
| ClinicalTrials.gov Identifier: | NCT01086475 History of Changes |
| Other Study ID Numbers: | 0906-09 |
| Study First Received: | March 10, 2010 |
| Last Updated: | April 16, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Asperger Syndrome Autistic Disorder Developmental Disabilities Child Development Disorders, Pervasive Mental Disorders Diagnosed in Childhood Mental Disorders Cycloserine Anti-Infective Agents, Urinary Anti-Infective Agents |
Therapeutic Uses Pharmacologic Actions Renal Agents Antibiotics, Antitubercular Anti-Bacterial Agents Antitubercular Agents Antimetabolites Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013